• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

AllianceRx Walgreens Pharmacy Selected to Distribute Vivjoa

News
Article

Vivjoa is an azole antifungal to reduce the incidence of chronic vaginal yeast infection in postmenopausal women.

Mycovia Pharmaceuticals has chosen AllianceRx Walgreens Pharmacy and Walgreens community-based specialty pharmacies to be the exclusive distributor of Vivjoa (oteseconazole). Vivjoa is an azole antifungal to reduce the incidence of chronic vaginal yeast infection in postmenopausal women.

Yeast infections are caused by Candida albicans. Nearly 75% of all adult women will have at least one yeast infection in their lifetime, with about half experiencing a recurrence. Of those, up to 9% develop recurrent infections, which is defined as having four or more infections in one year.

Vivjoa is designed to inhibit fungal CYP51, which is required for fungal cell wall integrity, and this results in the inhibition of fungal growth. Mycovia Pharmaceuticals launched Vivjoa in July 2022. The cost is about $3,085 for a supply of 18 capsules, according to Drugs.com. Commercially insured patients may be eligible to pay $5 for a 12-week course of Vivjoa.

A recent phase 3 study found Vivjoa was better at treating severe vaginal yeast infections than fluconazole, a commonly used antifungal to treat yeast infections, in Chinese women. The results from this head-to-head study were published in the journal Antimicrobial Agents and Chemotherapy.

“The results also expand on available clinical susceptibility data by demonstrating potent MIC activity of oteseconazole against wild-type and resistant Candida albicans isolates from this patient population, in addition to clinical isolates resistant to fluconazole, including Candida glabrata,” Stephen Brand, Ph.D., chief development officer at Mycovia, said in a news release.

MIC is a measure of susceptibility or resistance of an organism to the antifungal agent.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.